Recent Updates
Recently added Catalysts

SRP-9004

Phase 1

Limb-Girdle Muscular Dystrophy, Type 2D | Gene therapy | Neurology |Sarepta Therapeutics, Inc.|Last Updated: Jun 15, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDBiomarker
Total Trials1
Total Enrollment6
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01976091A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)PHASE1 COMPLETED 6Feb 1, 2015Mar 14, 2019Jun 15, 2023 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Adverse Events (AEs).
Up to 2 Years

An AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered study drug related. An AE was considered serious if, in the view of the investigator or sponsor, it resulted in any of the following outcomes: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Treatment-related Treatment Emergent Adverse Event (TEAE) is defined as an TEAE that was classified by the investigator as related to treatment.

Secondary Endpoints
Change From Baseline of the Distance Walked in 6 Minutes (6MWT)
Baseline, Up to 2 Years
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Cohort 1A: SRP-9004 Low Dose (Single Limb Perfusion)EXPERIMENTALNon-ambulant participants with LGMD2D will receive 1 low dose of SRP-9004 via ILI to a single limb on Day 0.
Cohort 1B Low Dose (Bilateral Limb Perfusion)EXPERIMENTALParticipants with LGMD2D will receive 1 low dose of SRP-9004 via ILI to both limbs on Day 0.
Cohort 2 High Dose (Bilateral Limb Perfusion)EXPERIMENTALParticipants with LGMD2D will receive 1 high dose of SRP-9004 via ILI to both limbs on Day 0.
Interventions
NameTypeDescription
SRP-9004GENETICIsolated Limb Infusion (ILI)
Unlock Study Design Details
Eligibility Criteria
Age Range7 Years — N/A
SexALL
Healthy VolunteersNo

Key Inclusion Criteria: * Cohort 1A must be adult and wheelchair-dependent; Cohorts 1B and 2 will be participants of age 7 or older. * Confirmed alpha-sarcoglycan deficiency or identified sarcoglycan alpha (SGCA) deoxyribonucleic acid (DNA) mutation. * Participants enrolled in Cohorts 1B or 2 must ...

Unlock Eligibility Criteria